SCHEMBL4683657

SCHEMBL4683657

COc1ccc(O)cc1/C=C/C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.74
CAPN1 P07384 1/20 0.70
MAPT P10636 3/20 0.59
APP P05067 2/20 0.59
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 3/20 0.57
HPGD P15428 2/20 0.57
ALOX15 P16050 2/20 0.57
HSD17B10 Q99714 2/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
JUN P05412 1/20 0.55
NFKB1 P19838 1/20 0.55
PKM P14618 2/20 0.54
PTGS1 P23219 1/20 0.54
PTGS2 P35354 1/20 0.54
MIF P14174 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4683661 1.00 BACE1 (0.74) BACE1CAPN1MAPTAPPKDM4E
SCHEMBL20152991 0.88 BACE1 (0.77) BACE1CAPN1MAPTAPPKDM4E
SCHEMBL1171571 0.87 APP (0.74) BACE1CAPN1MAPTAPPALDH1A1
SCHEMBL15238997 0.87 APP (0.74) BACE1CAPN1MAPTAPPALDH1A1
SCHEMBL1171573 0.87 APP (0.74) BACE1CAPN1MAPTAPPALDH1A1
SCHEMBL3218814 0.85 BACE1 (1.00) BACE1CAPN1MAPTAPP
SCHEMBL27890681 0.85 BACE1 (0.77) BACE1CAPN1MAPTAPPKDM4E
SCHEMBL27890682 0.85 BACE1 (0.77) BACE1CAPN1MAPTAPPKDM4E
SCHEMBL3218840 0.85 BACE1 (1.00) BACE1CAPN1MAPTAPP
SCHEMBL344708 0.84 BACE1 (0.54) BACE1CAPN1MAPTAPPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386913-B1 PYRROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2008-07-16 EP disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-20040162331-A1 Pyrrole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-08-19 US disclosed
EP-1386913-A1 PYRROLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162331-A1 Pyrrole derivative SLC5A1, GLP1R, SLC5A2 BACE1 2505/4885CAPN1 1537/4885MAPT 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.